China
FDA will work with China to import cancer drugs due to U.S. shortages
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
China
Analysis: Biden unlikely to sanction Iran’s oil exports, gas prices ‘critical during an election year’
Analysts say President Joe Biden is unlikely to “prompt dramatic sanctions action on Iran’s oil exports” due to “worries about boosting oil prices and angering top buyer China” according to Reuters.
Speaking to Fox News on Sunday, House Republican Representative Steve Scalise, said the administration had made it easier for Iran to sell its oil, generating revenues that were being used to “go fund terrorist activity.”
The Biden administration has maintained for months that among its primary goals is to keep the Gaza conflict between terror group Hamas and Israel from turning into a wider regional war. However, House Republican leaders accused President Joe Biden of failing to enforce existing measures and said they would take up this week a series of bills to sharpen sanctions on Iran.
Kimberly Donovan, a sanctions and anti-money laundering expert at the Atlantic Council, said that oil-related sanctions have not been strictly enforced in the past couple of years.
“I would not expect the administration to tighten enforcement in response to Iran’s missile and drone attacks against Israel over the weekend, mainly for concerns (that) could lead to increases in oil prices,” she said.
-
education7 days agoStates are suing Joe Biden over student-debt plan
-
Israel6 days agoHamas tells mediators it does not have the 40 hostages required for cease-fire
-
Economy5 days agoFederal Reserve Economist on hidden camera: ‘we don’t want Trump to be in the government’
-
education6 days agoHarvard Reinstates Standardized Testing Requirement for Admissions
